Data needs to be more organized so it is more available and useful at the point of care, said Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
Transcript (slightly modified)
With all the data now available, how can we ensure that it is used at the point of care to improve care delivery?
There’s so much data available. First of all, it needs to be cleaned up, so that by the time the data gets back to doctor and patient, it’s something that’s sensible. So, in order to make it available and useful for a point of care, it needs to be cleaned up and put into order. It needs to be analyzed and information needs to be presented to doctors and patients directly in the electronic health record or in dashboards that summarize, for example, what treatments patients have been receiving and how patients that look like this person sitting in front of me, have fared on Treatment A versus Treatment B.
So, that set of activities which include data, cleaning and organization, as well as getting to the point of having analyses we can rely on and being presented in dashboards and other methods to make is easy at point-of-care, is going to be the way that data starts to change care. The first steps are there but I think we’ve got a long way to go.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More